Contagion Live news stories
Switching to doravirine/islatravir maintains viral suppression through 96 weeks (MK-8591A-051 study)
New 96-week data from the open-label, phase 3 MK-8591A-051 study demonstrate that switching to the fixed-dose combination of doravirine and islatravir (DOR/ISL, 100/0.25 mg) continues to support durable viral suppression and long-term tolerability in adults with HIV who were previously virologically suppressed on oral antiretroviral therapy.
Doravirine/islatravir combination maintains virologic suppression through 96 weeks (MK-8591A-052 study)
The 96-week data from the double-blind, phase 3 MK8591A-052 trial show that switching to doravirine/islatravir maintained durable virologic suppression with efficacy and safety comparable to continuing bictegravir/emtricitabine/tenofovir alafenamide.
View all Contagion Live reports from CROI 2026
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.